Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41420-025-02415-x.

Title:
Ferroptosis: CD8+T cells’ blade to destroy tumor cells or poison for self-destruction | Cell Death Discovery
Description:
Ferroptosis represents an emerging, iron-dependent form of cell death driven by lipid peroxidation. In recent years, it has garnered significant attention in the realm of cancer immunotherapy, particularly in studies involving immune checkpoint inhibitors. This form of cell death not only enhances our comprehension of the tumor microenvironment but is also considered a promising therapeutic strategy to address tumor resistance, investigate immune activation mechanisms, and facilitate the development of cancer vaccines. The combination of immunotherapy with ferroptosis provides innovative targets and fresh perspectives for advancing cancer treatment. Nevertheless, tumor cells appear to possess a wider array of ferroptosis evasion strategies compared to CD8+T cells, which have been conclusively shown to be more vulnerable to ferroptosis. Furthermore, ferroptosis in the TME can create a favorable environment for tumor survival and invasion. Under this premise, both inducing tumor cell ferroptosis and inhibiting T cell ferroptosis will impact antitumor immunity to some extent, and even make the final result run counter to our therapeutic purpose. This paper systematically elucidates the dual-edged sword role of ferroptosis in the antitumor process of T cells, briefly outlining the complexity of ferroptosis within the TME. It explores potential side effects associated with ferroptosis-inducing therapies and critically considers the combined application of ferroptosis-based therapies with ICIs. Furthermore, it highlights the current challenges faced by this combined therapeutic approach and points out future directions for development.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,797,153 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$539,300 per month
Our calculations suggest that Nature.com earns between $359,538 and $988,730 monthly online from display advertisements.

Keywords {🔍}

cells, ferroptosis, pubmed, article, google, scholar, cancer, tumor, cell, cas, central, immune, cdt, antitumor, lipid, immunotherapy, death, immunity, levels, effects, pathway, chen, peroxidation, treatment, therapy, zhang, expression, function, nature, tme, role, therapeutic, activation, dcs, gpx, wang, ferroptotic, microenvironment, accumulation, activity, resistance, iron, liu, mechanisms, targeting, response, induce, promoting, nat, zhao,

Topics {✒️}

nature portfolio privacy policy open-label keynote-021 study editing long-chain acyl-coa synthetases wnt/β-catenin-mitf pathway advertising unrestrained proliferative nature peroxisome proliferator-activated receptor-gamma barnawi io atf4-chop-chac1 signaling pathway anti-pd-l1 immunotherapy-activated cd8+ pd-1/pd-l1 checkpoint inhibitors social media jama netw open cell-mediated anti-tumor immunity lactate-mediated ampk-scd1 activity reprints middle calcium-independent phospholipase a2β pd-1/pd-l1 bockade dual-edged sword role gcn2-eif2α-atf4 pathway myeloid-derived suppressor cells limiting nf-κb recruitment triple-negative breast cancer nature pd-1/pd-l1 inhibitors significant research gap kras-mutant lung adenocarcinoma jak1-stat1 signaling pathway anti-tumor immune responses mitochondrial iron-sulfur cluster current antitumor research fatty acid oxidation oxidized low-density lipoprotein author information authors small-cell lung cancer important research topic p53-independent tumor suppression image-guided drug delivery jak-stat1-irf1 pathway resist ferroptosis-inducing therapies personal data received official approval ros/acetyl-p53 pathway real-time treatment monitoring inducing epithelial-mesenchymal transformation data protection vhl-defective ccrcc cells

Questions {❓}

  • Can tumor cells be specifically induced to undergo ferroptosis without affecting normal antitumor immune cells?
  • How can ferroptosis be utilized to reverse the immunosuppressive microenvironment and protect the antitumor effects of immune cells?
  • How can we design standardized and reasonable clinical translation experiments based on the atypia and heterogeneity of tumors, and explore reliable biomarkers to predict patients’ responses to ferroptosis-combined immunotherapy?
  • How can we minimize the toxic and side effects caused by derivatives of ferroptotic cancer cells?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Ferroptosis: CD8+T cells’ blade to destroy tumor cells or poison for self-destruction
         description:Ferroptosis represents an emerging, iron-dependent form of cell death driven by lipid peroxidation. In recent years, it has garnered significant attention in the realm of cancer immunotherapy, particularly in studies involving immune checkpoint inhibitors. This form of cell death not only enhances our comprehension of the tumor microenvironment but is also considered a promising therapeutic strategy to address tumor resistance, investigate immune activation mechanisms, and facilitate the development of cancer vaccines. The combination of immunotherapy with ferroptosis provides innovative targets and fresh perspectives for advancing cancer treatment. Nevertheless, tumor cells appear to possess a wider array of ferroptosis evasion strategies compared to CD8+T cells, which have been conclusively shown to be more vulnerable to ferroptosis. Furthermore, ferroptosis in the TME can create a favorable environment for tumor survival and invasion. Under this premise, both inducing tumor cell ferroptosis and inhibiting T cell ferroptosis will impact antitumor immunity to some extent, and even make the final result run counter to our therapeutic purpose. This paper systematically elucidates the dual-edged sword role of ferroptosis in the antitumor process of T cells, briefly outlining the complexity of ferroptosis within the TME. It explores potential side effects associated with ferroptosis-inducing therapies and critically considers the combined application of ferroptosis-based therapies with ICIs. Furthermore, it highlights the current challenges faced by this combined therapeutic approach and points out future directions for development.
         datePublished:2025-04-01T00:00:00Z
         dateModified:2025-04-01T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/s41420-025-02415-x
         keywords:
            Immune cell death
            Targeted therapies
            Tumour immunology
            Life Sciences
            general
            Biochemistry
            Cell Biology
            Stem Cells
            Apoptosis
            Cell Cycle Analysis
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig4_HTML.png
         isPartOf:
            name:Cell Death Discovery
            issn:
               2058-7716
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yuan Liang
               affiliation:
                     name:Changchun
                     address:
                        name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yixin Zhao
               affiliation:
                     name:Changchun
                     address:
                        name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhaoyang Qi
               affiliation:
                     name:Changchun
                     address:
                        name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xinru Li
               affiliation:
                     name:Changchun
                     address:
                        name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuguang Zhao
               url:http://orcid.org/0000-0002-4430-7798
               affiliation:
                     name:Changchun
                     address:
                        name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Ferroptosis: CD8+T cells’ blade to destroy tumor cells or poison for self-destruction
      description:Ferroptosis represents an emerging, iron-dependent form of cell death driven by lipid peroxidation. In recent years, it has garnered significant attention in the realm of cancer immunotherapy, particularly in studies involving immune checkpoint inhibitors. This form of cell death not only enhances our comprehension of the tumor microenvironment but is also considered a promising therapeutic strategy to address tumor resistance, investigate immune activation mechanisms, and facilitate the development of cancer vaccines. The combination of immunotherapy with ferroptosis provides innovative targets and fresh perspectives for advancing cancer treatment. Nevertheless, tumor cells appear to possess a wider array of ferroptosis evasion strategies compared to CD8+T cells, which have been conclusively shown to be more vulnerable to ferroptosis. Furthermore, ferroptosis in the TME can create a favorable environment for tumor survival and invasion. Under this premise, both inducing tumor cell ferroptosis and inhibiting T cell ferroptosis will impact antitumor immunity to some extent, and even make the final result run counter to our therapeutic purpose. This paper systematically elucidates the dual-edged sword role of ferroptosis in the antitumor process of T cells, briefly outlining the complexity of ferroptosis within the TME. It explores potential side effects associated with ferroptosis-inducing therapies and critically considers the combined application of ferroptosis-based therapies with ICIs. Furthermore, it highlights the current challenges faced by this combined therapeutic approach and points out future directions for development.
      datePublished:2025-04-01T00:00:00Z
      dateModified:2025-04-01T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/s41420-025-02415-x
      keywords:
         Immune cell death
         Targeted therapies
         Tumour immunology
         Life Sciences
         general
         Biochemistry
         Cell Biology
         Stem Cells
         Apoptosis
         Cell Cycle Analysis
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41420-025-02415-x/MediaObjects/41420_2025_2415_Fig4_HTML.png
      isPartOf:
         name:Cell Death Discovery
         issn:
            2058-7716
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yuan Liang
            affiliation:
                  name:Changchun
                  address:
                     name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yixin Zhao
            affiliation:
                  name:Changchun
                  address:
                     name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhaoyang Qi
            affiliation:
                  name:Changchun
                  address:
                     name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xinru Li
            affiliation:
                  name:Changchun
                  address:
                     name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuguang Zhao
            url:http://orcid.org/0000-0002-4430-7798
            affiliation:
                  name:Changchun
                  address:
                     name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cell Death Discovery
      issn:
         2058-7716
      volumeNumber:11
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Changchun
      address:
         name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
         type:PostalAddress
      name:Changchun
      address:
         name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
         type:PostalAddress
      name:Changchun
      address:
         name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
         type:PostalAddress
      name:Changchun
      address:
         name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
         type:PostalAddress
      name:Changchun
      address:
         name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yuan Liang
      affiliation:
            name:Changchun
            address:
               name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
               type:PostalAddress
            type:Organization
      name:Yixin Zhao
      affiliation:
            name:Changchun
            address:
               name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
               type:PostalAddress
            type:Organization
      name:Zhaoyang Qi
      affiliation:
            name:Changchun
            address:
               name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
               type:PostalAddress
            type:Organization
      name:Xinru Li
      affiliation:
            name:Changchun
            address:
               name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
               type:PostalAddress
            type:Organization
      name:Yuguang Zhao
      url:http://orcid.org/0000-0002-4430-7798
      affiliation:
            name:Changchun
            address:
               name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
      name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
      name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
      name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China
      name:Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China

Social Networks {👍}(1)

External Links {🔗}(568)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

6.34s.